Pharmafile Logo

rare blood disease

- PMLiVE

Novartis’ Fabhalta recommended by CHMP to treat rare blood disorder PNH

Paroxysmal nocturnal haemoglobinuria affects approximately ten to 20 people per million worldwide

- PMLiVE

AstraZeneca’s Voydeya receives CHMP recommendation for rare blood disease PNH

Up to 20% of PNH patients treated with a C5 inhibitor experience clinically significant extravascular haemolysis

- PMLiVE

Roche and Exelis/Ipsen’s drug combination shows promise in phase 3 prostate cancer study

Around 299,000 new cases of prostate cancer will be diagnosed in the US in 2024

- PMLiVE

Roche’s Genentech and GenEdit enter autoimmune disease partnership worth up to $644m

The companies will develop nanoparticles to deliver genetic medicines for autoimmune diseases

- PMLiVE

New framework establishes two tests for use in clinical trials for Parkinson’s

The neurological condition currently affects around 145,000 people in the UK

- PMLiVE

Roche’s subcutaneous Tecentriq granted EC approval for multiple cancer types

The formulation reduces treatment time by around 80% compared to intravenous infusion

- PMLiVE

New antibiotic compound could potentially treat lethal hospital infections

Zosurabalpin successfully eliminated the multi-resistant A baumannii bacteria

- PMLiVE

Study programme to investigate blocking brain inflammation in Parkinson’s patients

If successful, the findings could lead to new medicines to treat the neurological disease

- PMLiVE

Roche shares positive late-stage results for inavolisib combination in advanced breast cancer

About 290,000 people in the US will be diagnosed with breast cancer in 2023

- PMLiVE

Novartis’ Fabhalta approved by FDA as first oral monotherapy for rare blood disease PNH

The rare blood disease is estimated to affect only ten to 20 people per million worldwide

- PMLiVE

Roche to acquire Carmot Therapeutics in deal worth up to $3.1bn

The company will gain access to a portfolio of incretin-based therapies for diabetes and obesity

- PMLiVE

Roche’s subcutaneous Tecentriq recommended by CHMP for multiple cancer types

The formulation can cut treatment time by approximately 80% compared to intravenous infusion

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links